Northwest Biotherapeutics (NWBO) Equity Ratio (2016 - 2025)
Northwest Biotherapeutics (NWBO) has 16 years of Equity Ratio data on record, last reported at 3.55 in Q3 2025.
- For Q3 2025, Equity Ratio fell 29.91% year-over-year to 3.55; the TTM value through Sep 2025 reached 3.55, down 29.91%, while the annual FY2024 figure was 3.54, 49.77% down from the prior year.
- Equity Ratio reached 3.55 in Q3 2025 per NWBO's latest filing, down from 3.4 in the prior quarter.
- Across five years, Equity Ratio topped out at 1.7 in Q1 2023 and bottomed at 12.16 in Q2 2021.
- Average Equity Ratio over 5 years is 4.33, with a median of 3.4 recorded in 2025.
- Peak YoY movement for Equity Ratio: plummeted 173.16% in 2021, then skyrocketed 72.61% in 2022.
- A 5-year view of Equity Ratio shows it stood at 3.09 in 2021, then crashed by 32.46% to 4.09 in 2022, then surged by 42.28% to 2.36 in 2023, then tumbled by 49.77% to 3.54 in 2024, then decreased by 0.41% to 3.55 in 2025.
- Per Business Quant database, its latest 3 readings for Equity Ratio were 3.55 in Q3 2025, 3.4 in Q2 2025, and 3.62 in Q1 2025.